Two drugs to raise platelets before surgery in liver disease
Part of Blood & lymphatic clinical trials.
This trial tests two medications (lusutrombopag and recombinant human thrombopoietin) given together to raise platelet levels before a planned surgery in people with chronic liver disease. The goal is to reduce the need for platelet transfusions and make the procedure safer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic liver disease and a low platelet count (35,000 or fewer).
- You are scheduled for an elective, non-emergency invasive procedure (like a biopsy or endoscopy) that is planned 9–15 days after starting the study drugs.
- You have not had a blood clot, do not have a condition that raises clot risk, and have not had a liver transplant.
- You do not have active cancer that requires chemotherapy, radiation, or other cancer treatments during the study.
- You are not on certain medications (like blood thinners or other experimental drugs) in the 90 days before the study begins.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the drug hetrombopag can safely raise platelet counts in people with immune thrombocytopenia (ITP) before they have surgery. The goal is to reduce bleeding risk during and after the operation.
This trial tests a drug called avatrombopag (a pill) to help raise platelet counts in people who develop very low platelets after a stem cell transplant from a half-matched donor (haplo-HSCT). It aims to see if the drug is safe and effective at reducing the need for platelet transfusions.
This trial studies whether avatrombopag can help your platelet count recover after a bone marrow transplant from an unrelated donor (UCBT) in certain bone marrow failure diseases. If platelets recover better, it may reduce risks related to low platelets after transplant.
This study tests a new medicine called PN20 to safely raise platelet counts in people with chronic liver disease who need a minor procedure (like a biopsy). It's for patients whose platelet count is below 50 and whose liver disease is not too severe.
This study tests if a combination of two medications, hetrombopag (a pill) and rhTPO (an injection), can safely raise very low platelet counts in people with solid tumors caused by their cancer treatments. If you have low platelets due to chemo, radiation, or other therapies, this may offer a new option.
This Phase 2 study tests eltrombopag to help people with low platelet counts caused by chemotherapy (which can increase bleeding risk). It looks at whether raising platelets can reduce bleeding problems and help you stay on track with care.
Hear when a new Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.